Browse > Article
http://dx.doi.org/10.5806/AST.2022.35.3.93

Analytical methods to manage potential impurities in drug substances  

Park, Kyung Min (College of Pharmacy, Kyung Hee University)
Kim, Won Mi (College of Pharmacy, Kyung Hee University)
Ahn, Su Hyun (College of Pharmacy, Kyung Hee University)
Lee, Ha Lim (College of Pharmacy, Kyung Hee University)
Hwang, Su Hyeon (College of Pharmacy, Kyung Hee University)
Lee, Wonwoong (College of Pharmacy, Woosuk University)
Hong, Jongki (College of Pharmacy, Kyung Hee University)
Publication Information
Analytical Science and Technology / v.35, no.3, 2022 , pp. 93-115 More about this Journal
Abstract
Potential impurities in pharmaceuticals could be produced during manufacture, distribution, and storage and affect quality and safety of pharmaceuticals. In particular, highly reactive impurities could result in carcinogenic (mutagenic) effects on human body. International Conference on Harmonisation (ICH) has provided M7(R1) guideline for "Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk" and recommended an adoption of this guideline to the authorities. ICH M7(R1) guideline provides classification, accepted intakes, and controls of potential impurities in pharmaceuticals. However, since appropriate and unified analytical methods for impurities in pharmaceuticals have not been provided in this guideline, most potential impurities in pharmaceuticals are still difficult to manage and supervise by pharmaceutical companies and regulatory authorities, respectively. In this review, we briefly described definition of unintended mutagenic impurities, basic information in ICH M7(R1) guideline, and analytical methods to determine potential impurities. This review would be helpful to manage and supervise potential impurities in pharmaceuticals by pharmaceutical companies and regulatory authorities.
Keywords
potential impurity; mutagenic (carcinogenic) impurity; active pharmaceutical ingredient; drug substance; ICH M7(R1); analytical method;
Citations & Related Records
연도 인용수 순위
  • Reference
1 J. P. Guzowski Jr, C. Golanoski and E. R. Montgomery, J. Pharm. Biomed. Anal., 33, 963-974 (2003).   DOI
2 M. Song, S. Wu, P.-b. Lu, Y.-n. Qiao and T.-j. Hang, Anal. Methods, 8, 8352-8361 (2016).   DOI
3 T. Kumar, M. Ramya, V. Srinivasan and N. Xavier, J. Chromatogr. Sci., 55(7), 683-689 (2017).   DOI
4 S. S. Kumar and R. K. Srivastava, Indian J. Pharm. Sci., 80(4), 744-749 (2018).
5 Z. Li, L. K. Jacobus, W. P. Wuelfing, M. Golden, G. P. Martin and R. A. Reed, J. Chromatogr. A, 1104, 1-10 (2006).   DOI
6 J. Diekmann, C. Biefel and K. Rustemeier, J. Chromatogr. Sci., 40(9), 509-514 (2002).   DOI
7 K. S. Sidhu, J. Appl. Polym. Sci., 1(6), 300-302 (1981).
8 J. L. Lunde, R. E. Nelson and H. F. Storandt, Pharmacotherapy, 27, 1202-1205 (2007).   DOI
9 S. R. Reddy, K. H. Reddy, M. N. Kumar, P. M. Reddy, J. V. R. Reddy and H. K. Sharma, J. Chromatogr. Sci., 57(2), 101-107 (2019).   DOI
10 S. Sleijfer, I. Ray-Coquard, Z. Papai, A. Le Cesne, M. Scurr, P. Schoffski, F. Collin, L. Pandite, S. Marreaud, A. De Brauwer, M. van Glabbeke, J. Verweij and J.-Y. Blay, Clin. J. Oncol. Nurs., 27, 3126-3132 (2009).   DOI
11 IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man, vol 7, Some Anti-Thyroid and Related Substances, Nitrofurans and Industrial Chemicals, https://publications.iarc.fr/Book-And-Report-Series/Iarc-Monographs-On-The-Identification-Of-Carcinogenic-Hazards-To-Humans/Some-Anti-Thyroid-And-Related-Substances-Nitrofurans-And-Industrial-Chemicals-1974, Accessed 9 Sep 2021.
12 K. Hamada and H. Morishita, Sepctrosc. Lett., 13(6), 373-380 (1980).   DOI
13 The National Institute for Occupational Safety and Health (NIOSH), Sodium Azide: Systemic Agent, https://www.cdc.gov/niosh/ershdb/emergencyresponsecard_29750027.html, Assessed 13 Aug 2021.
14 International Programme on Chemical Safety (IPCS), Concise International Chemical Assessment Document, https://inchem.org/documents/cicads/cicads/cicad42.htm., Accessed 15 Sep 2021.
15 J. P. Bercu, S. M. Galloway, P. Parris, A. Teasdale, M. Masuda-Herrera, K. Dobo, P. Heard, M. Kenyon, J. Nicolette, E. Vock, W. Ku, J. Harvey, A. White, S. Glowienke, E. A. Martin, L. Custer, R. A. Jolly and V. Thybaud, Regul. Toxicol. Pharmacol. 94, 172-182 (2018).   DOI
16 식품의약품안전처, 의약품 불순물 유전독성 평가 가이드라인 [민원인 안내서] 2017. 10., https://www.mfds.go.kr/brd/m_1060/view.do?seq=13434&srchFr=&srchTo=&srchWord=%EC%9D%98%EC%95%BD%ED%92%88+%EB%B6%88%EC%88%9C%EB%AC%BC+%EC%9C%A0%EC%A0%84%EB%8F%85%EC%84%B1+%ED%8F%89%EA%B0%80+%EA%B0%80%EC%9D%B4%EB%93%9C%EB%9D%BC%EC%9D%B8&srchTp=0&itm_seq_1=0&itm_seq_2=0&multi_itm_seq=0&company_cd=&company_nm=&Data_stts_gubun=C9999&page=1, Assessed 2 Aug 2021.
17 N. Li and J. Zou, J. Appl. Polym. Sci., 100(4), 3141-3144 (2005).   DOI
18 M. Maithani, R. Raturi, V. Gupta and P. Bansal, J. Liq. Chromatogr. Relat. Technol., 40(15), (2017).
19 D. Q. Liu, M. Sun and A. S. Kord, J. Pharm. Biomed. Anal., 51, 999-1014 (2010).   DOI
20 M. Shelke, S. S. Deshpande and S. Sharma, Crit. Rev. Anal. Chem., 50(3), 226-253 (2020).   DOI
21 European Medicines Agency, ICH guideline M7(R1) on assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk, https://www.ema.europa.eu/en/documents/scientific-guideline/ich-guideline-m7r1-assessment-control-dna-reactive-mutagenic-impurities-pharmaceuticals-limit_en.pdf, Assessed 2 Aug 2021.
22 Health Canada, Multiple lots of irbesartan, losartan and valsartan drugs recalled, https://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2021/75715aeng.php, Assessed 13 Aug 2021.
23 식품의약품안전처, [ICH Guideline] M7(R1) 잠재적 발암 위해를 제한하기 위한 의약품 중 DNA 반응성(변이원성) 불순물의 평가 및 관리, https://www.nifds.go.kr/brd/m_105/view.do?seq=30606&srchFr=&srchTo=&srchWord=&srchTp=&itm_seq_1=0&itm_seq_2=0&multi_itm_seq=0&company_cd=&company_nm=&page=3, Assessed 30 Aug 2021.
24 C. W. Felix, Food Protection Technology, p29-37, CRC Press, Boca Raton, 1987.
25 I. C. Munro, A. G. Renwick and B. Danielewska-Nikiel, Toxicol. Lett., 180, 151-156 (2008).   DOI
26 ICH, Guidelines M7 Mutagenic impurities, https://www.ich.org/page/multidisciplinary-guidelines, Assessed 2 Aug 2021.
27 N. Kumar and A. Jha, Saudi Pharm. J., 25, 176-183 (2017).   DOI
28 L. Muller, R. J. Mauthe, C. M. Riley, M. M. Andino, D. De Antonis, C. Beels, J. De George, A. G. M. De Knaep, D. Ellison, J. A. Fagerland, R. Frank, B. Fritschel, S. Galloway, E. Harpur, C. D. N. Humfrey, A. S. Jacks, N. Jagota, J. Mackinnon, G. Mohan, D. K. Ness, M. R. O'Donovan, M. D. Smith, G. Vudathala and L. Yotti, Regul. Toxicol. Pharmacol., 44, 198-211 (2006).   DOI
29 D. Jacobson-Kram and T. McGovern, Adv. Drug Deliv. Rev., 59, 38-42 (2007).   DOI
30 M. Stare, K. Laniewski, A. Westermark, M. Sjogren and W. Tian, Org. Process. Res. Dev., 13, 857-862 (2009).   DOI
31 Q. Yang, B. P. Haney, A. Vaux, D. A. Riley, L. Heidrich, P. He, P. Mason, A. Tehim, L. E. Fisher, H. Maag and N. G. Anderson, Org. Process. Res. Dev., 13(4), 786-791 (2009).   DOI
32 IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, vol 77, Some Industrial Chemicals, https://publications.iarc.fr/Book-And-Report-Series/Iarc-Monographs-On-The-Identification-Of-Carcinogenic-Hazards-To-Humans/Some-Industrial-Chemicals-2000, Accessed 4 Sep 2021.
33 A. Louie, Chem. Rev., 110, 3146-3195 (2010).   DOI
34 E. U. Stolarczyk, K. Eksanow and K. Filip, Anal. Lett., 49(14), 2337-2346 (2016).   DOI
35 IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, vol 71, Re-evaluation of Some Organic Chemicals, Hydrazine and Hydrogen Peroxide, https://publications.iarc.fr/Book-And-Report-Series/Iarc-Monographs-On-The-Identification-Of-Carcinogenic-Hazards-To-Humans/Re-evaluation-Of-Some-Organic-Chemicals-Hydrazine-And-Hydrogen-Peroxide-Part1-Part-2-Part-3--1999, Accessed 28 Sep 2021.
36 A. A. Ensafi and B. Rezaei, Talanta, 47, 645-649 (1998).   DOI
37 Y.-Y. Liu, I. Schmeltz and D. Hoffmann, Anal. Chem., 46(7), 885-889 (1974).   DOI
38 U. Balcik, D. S. Chormey, M. F. Ayyildiz and S. Bakirdere, Microchem. J., 155, 104712 (2020).   DOI
39 T. Kaleemullah, M. Ahmed, H. K. Sharma, K. V. S. N. Raju and M. N. Kumar, Der Pharma Chem., 3(6), 390-399 (2011).
40 J.-G. Yim, H.-W. Jang and K.-G. Lee, Korean J. Food Sci. Technol., 42(3), 257-262 (2010).
41 M. G. Choi, J. O. Moon, J. Bae, J. W. Lee and S.-K. Chang, Org. Biomol. Chem., 11(18), 2961-2965 (2013).   DOI
42 WMO. Scientific, Assessment of Ozone Depletion: 2006, https://csl.noaa.gov/assessments/ozone/2006/chapters/contentsprefaceexecutivesummary.pdf, Accessed 28 Sep 2021.
43 N. Yassaa, A. Wishkerman, F. Keppler and J. Williams, Environ. Chem., 6(4), 311-318 (2009).   DOI
44 Y.-y. Zhao, Z.-z. Jing, H.-p. Li and H.-s. Zhang, Microchem. J., 69(3), 213 -217 (2001).   DOI
45 H. H. W. Yang and A. Weisz, J. AOAC Int., 101(6), 1961-1966 (2018).   DOI
46 T. Huang, M. E. Garceau and P. Gao, J. Pharm. Biomed. Anal., 31, 1203-1210 (2003).   DOI
47 A. S. Ivanova, A. D. Merkuleva, S. V. Andreev and K. A. Sakharov, Food Chem., 283, 431-436 (2019).   DOI
48 H. Yue, X. Bu, M.-H. Huang, J. Young and T. Raglione, Int. J. Pharm., 375, 33-40 (2009).   DOI
49 K. Hori, N. Koriyama, H. Omori, M. Kuriyama, T. Arishima and K. Tsumura, Food Sci. Technol., 48, 204-208 (2012).
50 B. W. Manning, C. E. Cerniglia and T. W. Federlei, Appl. Environ. Microbiol., 50(1), 10-15 (1985).   DOI
51 N. Rajana, D. V. Ramana, R. R. Ganta, D. R. Devi, A. A. Deshpande, J. M. Babu and K. Basavaiah, Sep. Sci. Plus, 3(10), 511-522 (2020).   DOI
52 R. Peto, M. C. Pike, L. Bernstein, L. S. Gold and B. N. Ames, Environ. Health Perspect., 58, 1-8 (1984).   DOI
53 A. Teasdale and D. P. Elder, Trends Anal. Chem., 101, 66-84 (2018).   DOI
54 X. Zheng, W. Fu, K. Zheng, B. Gao, L. Lin, W. Liu, Z. Lin and Q. Fang, Food Control, 123, 107766 (2021).   DOI
55 S. P. Felter, R. B. Conolly, J. P. Bercu, P. M. Bolger, A. R. Boobis, P. M. J. Bos, P. Carthew, N. G. Doerrer, J. I. Goodman, W. A. Harrouk, D. J. Kirkland, S. S. Lau, G. C. Llewellyn, R. J. Preston, R. Schoeny, A. R. Schnatter, A. Tritscher, F. van Velsen and G. M. Williams, Crit. Rev. Toxicol., 41(6), 507-544 (2011).   DOI
56 Government of UK, Less than lifetime exposure: principles for consideration of risk, https://www.gov.uk/government/publications/less-than-lifetime-exposure-principles-for-consideration-of-risk, Assessed 31 Aug 2021.
57 B. Leblanc, C. Charuel, W. Ku and R. Ogilvie, Int. J. Pharm. Med., 18(4), 215-220 (2004).   DOI
58 P. A. Harris, A. Boloor, M. Cheung, R. Kumar, R. M. Crosby, R. G. Davis-Ward, A. H. Epperly, K. W. Hinkle, R. N. Hunter III, J. H. Johnson, V. B. Knick, C. P. Laudeman, D. K. Luttrell, R. A. Mook, R. T. Nolte, S. K. Rudolph, J. R. Szewczyk, A. T. Truesdale, J. M. Veal, L. Wang and J. A. Stafford, J. Med. Chem., 51, 4632-4640 (2008).   DOI
59 G. W. Aylward, Eye, 19, 1115-1118 (2005).   DOI
60 F. David, K. Jacq, P. Sandra, A. Baker and M. S. Klee, Anal. Bioanal. Chem., 396, 1291-1300 (2010).   DOI
61 H. G. Ramjit, M. M. Singh and A. B. Coddington, J. Mass Spectrom., 31(8), 867-872 (1996).   DOI
62 K. Ramakrishna, N. V. V. S. S. Raman, K. M. V. N. Rao, A. V. S. S. Prasad and K. S. Reddy, J. Pharm. Biomed. Anal., 46, 780-783 (2008).   DOI
63 P. R. Kakadiya, B. P. Reddy, V. Singh, S. Ganguly, T. G. Chandrashekhar and D. K. Singh, J. Pharm. Biomed. Anal., 55, 379-384 (2011).   DOI
64 National Toxicology Program, Bioassay of p-Chloroaniline for possible carcinogenicity, https://ntp.niehs.nih.gov/publications/reports/tr/100s/tr189/index.html?utm_source=direct&utm_medium=prod&utm_campaign=ntpgolinks&utm_term=tr189abs, Accessed 5 Oct 2021.
65 S. R. Khobare, V. Gajare, E. V. Reddy, R. Datrika, M. Banda, V. Siddaiah, S. S. Pachore, U. Timanna, V. H. Dahanukar and U. K. S. Kumar, Carbohydr. Res., 435, 1-6 (2016).   DOI
66 Z. Y. Yuabova, D. R. Holschlag, S. A. Rodriguez, C. Qin, V. V. Papov, F. Qiu, J. F. McCaffrey and D. L. Norwood, J. Liq. Chromatogr. Relat. Technol., 31, 2318-2330 (2008).   DOI
67 M. Gricar and S. Andrensek, J. Pharm. Biomed. Anal., 125, 27-32 (2016).   DOI
68 A. Sturaro, G. Parvoli, L. Doretti, C. Bancomina and C. Neonato, Org. Mass Spectrom., 29(10), 575-577 (1994).   DOI
69 W. Li, J. Chromatogr. A, 1046, 297-301 (2004).   DOI
70 S. Chang and S. H. Lamm, Int. J. Toxicol., 22, 175-186 (2003).   DOI
71 O. Wachelko, P. Szpotb and M. Zawadzki, J. Pharm. Biomed. Anal., 192, 113671 (2020).   DOI
72 식품의약품안전처, 고혈압치료제(사르탄류)와 금연 치료보조제(바레니클린) 안전성 조사 실시, https://www.mfds.go.kr/brd/m_99/view.do?seq=454744, Accessed 9 Sep 2021.
73 S. Fujimura, T. Sato and A. Watanabe, J. Antimicrob. Agents, 3(2), 1000138 (2017).
74 P. Aparna, S. V. Rao, K. M. Thomas, K. Mukkanti, P. B. Gupta, K. Rangarao, G. K. Narayan, T. Sandip and K. Upendra, Pharmazie, 65(5), 331-335 (2010).
75 H. Ono, K. Hisatani and K. Kamide, Polym. J., 25(3), 245-265 (1993).   DOI
76 T. D. Ho, P. M. Yehl, N. P. Chetwyn, J. Wang, J. L. Anderson and Q. Zhong, J. Chromatogr. A, 1361, 217-228 (2014).   DOI
77 D. C. Vu, T. L. Ho, P. H. Vo, G. Carlo, J. A. McElroy, A. N. Davis, S. C. Nagelg and C.-H. Lin, Anal. Methods, 10, 730-742 (2018).   DOI
78 H. Hiratsuka, T. Okamoto, S. Kuroda, T. Okutsu, H. Maeoka, M. Taguchi and T. Yoshinaga, Res. Chem. Intermed., 27(1), 137-153 (2001).   DOI
79 F. Bruner, G. Bertoni and C. Severini, Anal. Chem., 50(1), 53-55 (1978).   DOI
80 V. M. Vorotyntsev, G. M. Mochalov, M. A. Kolotilova, and E. V. Volkova, J. Anal. Chem., 61(9), 883-888 (2006).   DOI
81 M. A. Cardoso, M. L. D. Favero, J. C. Gasparetto, B. S. Hess, D. P. Stremel and R. Pontarolo, J. Liq. Chromatogr. Relat. Technol., 34, 1556-1567 (2015).
82 Z. Gajdosechova, Z. Mester and E. Pagliano, Anal. Chem. Acta, 1064, 40-46 (2019).   DOI
83 E. Helms, N. Arpaia and M. Widener, J. Chem. Educ., 84(8), 1328-1330 (2007).   DOI
84 식품의약품안전처, LC-MS/MS를 이용한 사르탄류 원료의약품 중 AZBT 시험법, http://nifds.go.kr/brd/m_18/view.do?seq=12584&srchFr=&srchTo=&srchWord=&srchTp=&itm_seq_1=0&itm_seq_2=0&multi_itm_seq=0&company_cd=&company_nm=&page=2, Accessed 9 Sep 2021.
85 W. J. Ehlhardt and J. J. Howbert, J. Pharmacol. Exp. Ther., 19(2), 366-369 (1990).
86 C. Chavis, C. De Gourcy and J.-L. Imbach, Carbohydr. Res., 135, 13-27 (1984).   DOI
87 H. Wang, G. J. Provan and K. Helliwell, J. Pharm. Biomed. Anal., 29, 387-392 (2002).   DOI
88 L. Homanen, Spectrochim. Acta Part A, 39(1), 77-84 (1983).   DOI
89 M. E. Tuttolomondo, A. Navarro, T. Pena, E. L. Varetti and A. Ben Altabef, J. Phys. Chem. A, 109, 7946-7956 (2005).   DOI
90 S. R. Reddy, K. H. Reddy, M. N. Kumar, P. M. Reddy, J. V. R. Reddy and H. K. Sharma, J. Chromatogr. Sci., 57(2), 101-107 (2019).   DOI
91 X. Du, W. Zhang, B. Liu, T. Liu, Y. Xiao, M. Taniguchi and Y.L. Ren, J. AOAC Int., 102(6), 1877-1883 (2019).   DOI
92 K. Hamada and H. Morishita, Sepctrosc. Lett., 13(6), 373-380 (1980).   DOI
93 N. Sheppa, Trans. Faraday Soc., 46, 533-539 (1950).   DOI
94 J. Forshed, B. Erlandsson and S. P. Jacobsson, Anal. Chim. Acta, 552, 160-165 (2005).   DOI
95 C. C. Camarasu, J. Pharm. Biomed. Anal., 23, 197-210 (1998).   DOI
96 R. J. Koopmans, R. Van Der Linden and E. F. Vansant, Polym. Eng. Sci., 22(14) 878-882 (1982).   DOI
97 J. I. Bryant, J. Chem. Phys., 40(11), 3195-3203 (1964).   DOI
98 R. L. Hudson and R. F. Ferrante, Mon. Notices Royal Astron. Soc., 492, 283-293 (2020).   DOI
99 O. J. Kingsford, J. Qian, D. Zhang, Y. Yi and G. Zhu, Anal. Methods, 10(45), 5372-5379 (2018).   DOI
100 J. Mitchell Jr and H. D. Deveraux, Anal. Chim. Acta, 100, 45-52 (1978).   DOI
101 H. Below, N. Lehan and A. Kramer, Microchim. Acta, 146, 129-135 (2004).   DOI
102 T. Platzek, C. Lang, G. Grohmann, U-S Gi. and W. Baltes, Hum. Exp. Toxicol., 18, 552-559 (1999).   DOI
103 K. P. Evans, A. Mathias, N. Mellor, R. Silvester and A. E. Williams, Anal. Chem., 47(6), 821-824 (1975).   DOI
104 J. Unwin and J. A. Groves, Anal. Chem., 68, 4489-4493 (1996).   DOI
105 P. Otero, S. K. Saha, A. Hussein, J. Barron and P. Murray, Food Anal. Methods, 10(4), 876-884 (2017).   DOI
106 M. Adosinda M. Martins, N. Lima, A. J. D. Silvestre and M. J. Queiroz, Chemosphere, 52, 967-973 (2003).   DOI
107 European Medicines Agency, Assessment report, https://www.ema.europa.eu/en/documents/variation-report/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-chmp-assessment-report_en.pdf, Assessed 13 Aug 2021.
108 Y.-J. Kang, M.-S. Kim, M.-T. Lee, S.-H. You, J.-E. Lee, J.-H. Eom and S.-Y. Jung, J. Pharmacoepidemiol. Risk Manag., 13(1), 10-16 (2021).   DOI
109 International Labour Organization, https://www.ilo.org/dyn/icsc/showcard.listCards3, Accessed 1 Oct 2021.
110 The National Institute for Occupational Safety and Health (NIOSH), https://www.cdc.gov/niosh/npg/default.html, Accessed 1 Oct 2021.
111 P. Ellis, M. Kenyon and K. Dobo, Regul. Toxicol. Pharmacol., 65(2), 201-213 (2013).   DOI
112 F. P. Guengerich, L. E. Geiger, L. L. Hogy and P. L. Wright, Cancer Res., 41, 4925-4933 (1981).
113 D. L. Vassilaros and T. J. Bzik, Environ. Sci. Technol., 25(5), 878-883 (1991).   DOI
114 M. Shibata, K. Inoue, Y. Yoshimura, H. Nakazawa and Y. Seto, Arch. Toxicol., 78, 301-305 (2004).   DOI
115 K. Ventura, A. Eisner and M. Adam, Cent. Eur. J. Public Health, 12, S86-S89 (2004).
116 R. P. Frost, M. S. Hussain and A. R. Raghani, J. Sep. Sci., 26, 1097-1103 (2003).   DOI
117 J. V. Henshaw, LCGC North America, 29(10), 914-924 (2011).
118 R. S. Gable, Addiction, 99(6), 686-696 (2004).   DOI
119 D. I. Robinson, Org. Process. Res. Dev., 14(4), 946-959 (2010).   DOI
120 K. C. Giiven and T. Gezgin, Acta Pharm. Sci., 47, 15-20 (2005).
121 T. Kojima and Y. Tanaka, Anal. Chem., 48, 1760-1762 (1976).   DOI
122 B. C. Ozkan, M. Firat, D. S. Chormey and S. Bakirdere, Microchem. J., 145, 84-89 (2019).   DOI
123 C. F. Poole, J. Chromatogr. A, 1296, 15-24 (2013).   DOI
124 C. C. Camarasu, M. Mezei-Szuts and G. B. Varga, J. Pharm. Biomed. Anal., 18, 623-638 (1998).   DOI
125 A. Gosar, T. Shaikh, S. Botkondle, N. Mahadik and R. Tole. Int. J. Pharm. Res. Health Sci., 7(5), 3068-3071 (2019).   DOI
126 M. Sun, L. Bai and D. Q. Liu, J. Pharm. Biomed. Anal., 49(2), 529-533 (2009).   DOI
127 G.-P. Yang, X.-L. Lu, G.-S. Song and X.-M. Wang, Chinese J. Anal. Chem., 38(5), 719-722 (2010).   DOI
128 X. Meng-Xia and L. Yuan, Spectrochim. Acta Part A, 58, 2817-2826 (2002).   DOI
129 National Toxicology Program, Toxicology and Carcinogenesis Studies of para-Chloroaniline Hydrochloride in F344/N Rats and B6C3F1 Mice (Gavage Studies), https://ntp.niehs.nih.gov/publications/reports/tr/300s/tr351/index.html?utm_source=direct&utm_medium=prod&utm_campaign=ntpgolinks&utm_term=tr351abs, Accessed 5 Oct 2021.
130 J. S. Bus and J. A Popp, Food Chem. Toxicol., 25, 619-626 (1987).   DOI
131 G. Szekely, M. C. A. De Sousa, M. Gil, F. C. Ferreira and W. Heggie, Chem. Rev., 115(16), 8182-8229 (2015).   DOI
132 L. Havlikova, L. Matysova, L. Novakova, R. Hajkova and P. Solich, J. Pharm. Biomed. Anal., 43, 1169-1173 (2007).   DOI
133 K. McAdam, H. Kimpton, S. Essen, P. Davis, C. Vas, C. Wright, A. Porter and B. Rodu, Chem. Cent. J., 9(13), (2015).
134 B. R. Basrani, S. Manek, D. Mathers, E. Fillery and R. N. S. Sodhi, J. Endod., 362, 312-314 (2010).
135 J. Zheng, W. A. Prittsa, S. Zhanga and S. Wittenbergerb, J. Pharm. Biomed. Anal., 50(5), 1054-1059 (2009).   DOI
136 B. Tay Y. Ping and H. A. Aziz, J. Surfactants. Deterg., 22(4), 751-756 (2019).   DOI
137 N. H. Petha, R. S. Lokhande, D. T. Seshadri and R. M. Patil, Microchem. J., 133, 506-509 (2017).   DOI